Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.05
-$0.06(-5.61%)
At close: 4:00 PM EST
$0.05
-$0.06(-5.61%)
Day’s Range― - ―
52-Week Range$0.01 - $0.18
Previous CloseN/A
Volume216.71K
Average Volume (3M)24.92K
Market Cap
$2.36M
Enterprise Value$835.32K
Total Cash (Recent Filing)$12.00K
Total Debt (Recent Filing)$511.00K
Price to Earnings (P/E)―
Beta-0.65
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding50,297,450
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.14
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformA proprietary liposomal delivery platform is a durable technical advantage for RNAi therapeutics because delivery is the core barrier to clinical success. Owning DNAbilize can improve target engagement across multiple programs, support licensing/partnering, and de-risks future clinical development paths over time.
Focused Hematologic PipelineConcentrating R&D on AML and related hematologic cancers builds deep domain expertise, streamlines trial design, and can accelerate regulatory interactions. A clear therapeutic focus increases attractiveness to collaborators and may shorten development timelines compared with unfocused pipelines.
Low Absolute Debt BurdenVery low measured debt reduces fixed financing obligations and interest risk, giving management flexibility to prioritize R&D spending. Over the medium term this lessens the chance that debt servicing constrains clinical programs, though capital needs remain for operations.
Bears Say
No Product RevenueAbsence of commercial revenue means the company lacks validated, recurring cash flows and must rely on financing to sustain R&D. This structural gap increases dilution risk, makes long-term planning dependent on capital markets, and leaves profitability distant and uncertain.
Negative Shareholders' EquityNegative equity and sharply reduced assets reflect capital depletion and materially weaker balance-sheet resilience. This condition constrains financing options, can impair counterparty confidence, and elevates insolvency risk if fundraising stalls, limiting strategic flexibility.
Reliance On External FinancingHeavy dependence on equity and other financings creates recurring dilution and ties program continuity to market access. If capital markets tighten or investor appetite wanes, clinical timelines could slip or programs be curtailed, making operational progress contingent on successful raises.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.17 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $2.36M.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 48 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on May 08, 2026. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.50% Other Institutional Investors
99.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---